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Abstract: This paper describes the effects of low intensity continuous ultrasound (LICU) on the
inflammatory response of mouse pancreatic tumor explants. While there are many reports focusing
on the application of low-intensity pulsed ultrasound (LIPUS) on cell cultures and tissues, the effects
of continuous oscillations on biological tissues have never been investigated. Here we present an
exploratory study of the effects induced by LICU on mouse pancreatic tumor explants. We show that
LICU causes significant upregulation of IFN-γ, IL-1β, and TNF-α on tumor explants. No detectable
effects were observed on tumor vasculature or collagen I deposition, while thermal and mechanical
effects were not apparent. Tumor explants responded as a single unit to acoustic waves, with spatial
pressure variations smaller than their size.
Keywords: low-intensity continuous ultrasound; bioeffects; inflammation; tumor; interferon-γ
interleukins; tumor necrosis factor-α (TNF-α); collagen I; vasculature
1. Introduction
Low-Intensity Pulsed Ultrasound (LIPUS) is widely used as an imaging tool in medicine at
low intensities (<3 W/cm2). It is a non-invasive and safe technique used extensively as a diagnostic
and therapeutic tool [1–5]. In regular clinical applications, the intensity of the ultrasound applied
ranges from about 0.03–1.0 W/cm2. LIPUS based on contrast-agents has been also applied for
imaging [6,7], with high efficiency results at frequencies ranging from 500 kHz and 2 MHz.
Different intensities of exposure have been used in the literature for therapeutic purposes such as
healing of bone-fracture or soft-tissue lesions, with dosages up to 2 W/cm2 without tissue damage,
and frequencies between 0.7 and 3.0 MHz. Various studies have reported LIPUS-induced cell growth
with proliferation and promotion of multi-lineage differentiation with cell expansion and differentiation
in tissue culture, including gingival cells [8,9], periodontal cells [10–12], cementoblastic cells [13,14],
chondrocytes [15,16] or mesenchymal stem cells [17,18]. Also, LIPUS effects on osteoblasts and
enhancement of angiogenesis [19,20] were reported. Some studies showed that LIPUS enhanced
cell expansion and differentiation in tissue culture [10,21,22]. However, the underlying molecular
mechanisms governing these LIPUS-induced effects on tissues and cells [4,5] still need to be
investigated. In addition, LIPUS effects on tumor samples have not been extensively investigated.
All these studies describe the use of conventional pulsed wave generators, typically used
for diagnosis methods, to know possible therapeutic effects in cells and tissues. They assume the
advantages of non-heating effects on the tissues due to these ultrasonic actuators and the time-gaps
between consecutive wave trains.
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However, cellular responses to low-intensity US are parameter-dependent, especially in the case
of low-intensity pulsed US. Very few studies have reported the influence of LIPUS treatment on the
effects induced in bio-samples, including the intensity of the acoustic wave and the pulse repetition
frequency [23–25] at frequencies close to 1 MHz. In particular, Chunmei et al. [25] recently investigated
(2016) the systematic effects of low-intensity pulsed US on the proliferation of HepG2 and 3T3 cells
in vitro by changing the intensity in the range of 0–1.2 W/cm2, PRF (1 and 100 Hz), and the duty cycle
(10%, 20%, and 50%) with a 1.06 MHz generator. They found increased cell proliferation at intensities
between 0.4 W/cm2 and 0.8 W/cm2 and PRF ~ 100 Hz, but higher intensities generated cell death,
while lower pulse repetition frequencies did not induce any detectable effect on the cells. This recent
study evidenced the need to know how the duty cycle affects the sample response.
It is a challenge to know the ultrasound effects by elongating the pulse repetition frequency until
reaching a limit condition of duty cycle of 100%, at which the distance between consecutive wave
trains disappears and the pulsed wave becomes a continuous wave. This challenge led us to perform
the current study.
In this paper, we have replaced pulsed waves with continuous low intensity waves at similar
frequency and intensity amplitudes. Hereafter, they will be referred to as Low-Intensity Continuous
Ultrasound (LICU). LICU maintains the cell vibration throughout the whole acoustic treatment, instead
of the intermittent oscillations induced by LIPUS with temporal gaps relaxing the cell oscillatory
motion. Thus, the limit condition of an infinite wave-train length was assumed for the continuous
wave used in our experiments.
Inflammation is critical for tumor progression. Many cancers arise in sites of infection, chronic
irritation, and inflammation. In addition, tumor cells have co-opted some of the signaling molecules of
the innate immune system, such as selectins, chemokines, and their receptors for invasion, migration,
and metastasis [26]. Hence, the establishment of a new technique that promotes a pro-inflammatory
response on tumors for future optimized therapies is of great interest.
We present, for the first time, an exploratory study of the effects of LICU on the inflammatory
response of mouse pancreatic tumor explants. We also present a description of the mechanical, thermal,
and molecular effects induced by LICU on these explants. We show that LICU causes significant
upregulation of IFN-γ, IL-1β, and TNF-α in pancreatic tumor explants. Furthermore, we assess the
LICU effects on tumor vasculature and collagen I deposition. We show that LICU is minimally invasive
to the tissues’ structure and morphology.
2. Materials and Methods
2.1. Ultrasound Exposure System: Chamber of Acoustic Actuation
Our experiments were performed in a small ultrasound exposure system consisting of an open
glass chamber of cylindrical geometry (Figure 1A—inner diameter of 10 mm, wall thickness of 1 mm,
and height of 4 mm) resonating at f ~ 1 MHz. It was activated by an ultrasonic actuator attached
also to the glass slide at a very short distance of 3 mm (Figure 1A): a piezoelectric ceramic Ferroperm
pz26 of rectangular area (30 mm × 15 mm × 1.5 mm) resonating in its thickness mode at a frequency
f = 1.009 MHz. Both, the chamber and piezoelectric actuator were mechanically connected through
the glass slide, thus allowing for the transmission of the ultrasonic vibrations from the piezoelectric
ceramic. The chamber was actuated at intensity levels close to 0.1 Watt/cm2, significantly lower than
a tissue injury threshold described in the literature for average intensities up to 30 kW/cm2 and with
a duration of 10 min [27]. At a frequency f = 1.09 MHz, a complex 2D acoustic pressure pattern was
established inside the chamber filled with liquid (with a 3 mm-height), with maximal amplitudes
of 0.29 MPa (dark areas in Figure 1B) and pressure nodes (bright areas in Figure 1B) separated at
distances smaller than 1 mm. Different pressure amplitudes were thus exerted on different parts of the
tumor explants within the chamber of treatment.
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Figure 1. (A) Photograph of the ultrasound exposure system. A cylindrical open chamber was 
formed using a crystal ring (with an inner diameter of 10 mm, wall thickness 1 mm, height 4 mm) 
glued onto a microscope slide. The cavity was activated by an ultrasonic actuator; a small 
piezoelectric ceramic Ferroperm pz26 of rectangular area (30 mm × 15 mm × 1.5 mm), resonant at a 
frequency close to 1 MHz, was placed also on the microscope slide and close to the chamber of 
treatment. (B) 3D acoustic pressure pattern formed inside the acoustic cavity when a continuous 
wave at f = 1009 kHz (resonance frequency) and a fixed voltage of VP-P = 10 V is applied. 
2.2. Pressure Amplitude Measurements 
The acoustic pressure amplitudes inside the acoustic chamber were measured with a high 
sensitivity (−211 dB re 1 V/µPa) needle hydrophone (Precision Acoustics LTD, Dorchester, UK,  
SN 1423, Φ = 0.2 mm PVDF) calibrated over the frequency range of 500 kHz to 20 MHz. The probes 
plug into a submersible preamplifier SN (PA 08072) with a 50 Ω output impedance to reduce the 
susceptibility to electromagnetic interference, thus allowing very long coaxial cable extensions 
whilst maintaining a nominal 8 dB voltage gain. The instantaneous pressure (P) was calculated from 
acquired voltage readings, taking into account the hydrophone sensitivity at the acoustic working 
frequency (AWF) [28]. 
A complex pressure pattern was established inside the acoustic chamber at a frequency of 1.009 
MHz, as shown in Figure 1B (filmed on aqueous suspension of polystyrene micron-sized particles). 
This pressure pattern presents spatial variations that include dark areas with maximal pressure 
amplitudes (of 0.29 MPa) and bright areas with pressure nodes where the particles collect.  
In most soft tissue interfaces only a small fraction of the pulse is reflected. The impedance of the 
pancreas Zpanc ~ 1.70 × 106 kg/m2 s [28] is close to that of the liquid in which is immersed  
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Figure 1. (A) Photograph of the ultrasound exposure system. A cylindrical open chamber was formed
using a crystal ring (with an inner diameter of 10 mm, wall thickness 1 mm, height 4 mm) glued onto
a microscope slide. The cavity was activated by an ultrasonic actuator; a small piezo lectric ceramic
Ferrop rm pz26 of rectangular rea (30 mm × 15 m × 1.5 mm), resonant a a fr quency close to
1 MHz, was placed also n the microscope slide and close to t chamber of treatment. (B) 3D acoustic
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2.2. Pressure Amplitude Measurements
The acoustic pressure amplitudes inside the acoustic chamber were measured with a high sensitivity
(−211 dB re 1 V/µPa) needle hydro hone (Precision Acoustics LTD, Dorchester, UK, SN 1423, Φ = 0.2 mm
PVDF) calibrated over the frequency rang of 500 kHz to 20 MHz. The probes p ug into a submersible
preamplifier SN (PA 08072) with a 50Ω output impedance to reduce th sceptibility to electromagnetic
interference, thus allowing very long coaxial cable extensions whilst maintaining a nominal 8 dB voltage
gain. The instantaneous pressure (P) was calculated from acquired voltage readings, taking into account
the hydrophone sensitivity at the acoustic working frequency (AWF) [28].
A complex pressure pattern was established inside the acoustic chamber at a frequency of
1.009 MHz, as shown in Figure 1B (filmed on aqueous suspension of polystyrene micron-sized particles).
This pressure pattern presents spatial variations that include dark areas with maximal pressure
amplitudes (of 0.29 MPa) and bri ht areas with pressure nodes where the particles collect.
In most soft tissue interface only a small fraction of the pulse is reflected. The impedance
of the pancreas Zpanc ~ 1.70 × 106 kg/m2 s [28] is close to that of the liquid in which is
immersed (Zliquid ~ 1.66 × 106 kg/m2 s), thus providing a very low reflectivity at the interface:
R =
(
Zpancreas−Zmedium
Zpancreas+Zmedium
)2 ∼ 3 × 10−3  1. A very small fraction of the pulse is reflected at their
interface, so that the pressure pattern within the chamber remained practically unaltered when the
tumor sample was introduced.
An average intensity amplitude of I = 0.1 Watt/cm2 was determined from the pressure amplitude
taking into account the size of the chamber that has a surface S ~ 0.4 cm2. The intensity I of the acoustic
wave is proportional to the square power of the pressure amplitude P0 of the incident wave:
I = P20 /2Z (1)
2.3. Attenuation of the Ultrasounds on the Samples
The attenuation inside the chamber is negligible due to its size. In fact, minimal variations of
the pressure amplitude measurements were detected by the needle hydrophone within a maximum
pressure location.
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The attenuation inside the tissue depends linearly on the ultrasound frequency and increases
with the sample volume. In our experiments it can be considered negligible due to the small size
of the tissue samples (thickness of 1 mm), which are much smaller than any organ, such as liver or
kidney, for which authors like Nightingale or Yarmolenko [27,29] reported acoustic attenuation of
α ~ 0.3–1 dB/MHz−1 cm−1. An injury threshold for organs exposed to ultrasounds has been reported
in the literature for average intensities: up to 30 kW/cm2 for a total duration of 10 min is safe in organs
such as kidneys. A spatial peak intensity threshold of 16,620 W/cm2 was needed before a statistically
significant portion of the samples showed injury. This is nearly seven times the 2400 W/cm2 maximum
output of the clinical prototype used to move kidney stones effectively in pigs and more than 30 times
the intensity generated in our acoustic resonator. Our experiments were performed at intensity levels
significantly lower than this tissue injury threshold.
2.4. Thermal Measurements within the Acoustic Chamber
Ultrasound application can induce some degree of heating. As the energy within the sound
wave passes down into the tissues, it causes molecular oscillations in the tissue that can result in
heat generation. The rate at which the temperature rises in tissues exposed to the ultrasound linearly
depends on the intensity of the acoustic wave I and the degree of absorption within the sample (defined
through the acoustic attenuation coefficient of the sample α), and is inversely proportional to the tissue
density ρ and specific heat Cm [30]:
T =
2a·I·t
Cv
+ T0 (2)
where T0 is the initial temperature of the sample before the actuation of the ultrasound, and t is the time
of treatment. Cm is close to ~3600 J/(kg K)~4.18 J/cm3 ◦C for biological tissues. In our experiments,
a thermocouple (Fluke 179 True RMS Multimeter, Norfolk, UK equipped with an adapter Fluke Type
K 80 AK-A, Norfolk, UK) was used to measure the spatial temperature inside the acoustic treatment
chamber over a period of 2 h.
2.5. Tumor Explant Preparation
The Massachusetts General Hospital Subcommittee on Research Animal Care approved all mouse
experiments. Human pancreatic (PANC-1) tumors were grown orthotopically in 8-week-old severe
combined immunodeficient mice (SCID) females. Tumors were grown in the mice until they reached
4–5 mm diameter. At this size, necrosis is minimal, but the tumors are large enough to allow multiple,
relatively homogenous tumor fragments to be generated from a single tumor. Tumors were then
resected and cut into fragments of equal area and thickness of 1 mm and placed into the acoustic
chamber in Dulbecco’s Modified Eagle’s Medium (DMEM). Tumor explants were exposed LICU for
120 min, while explants in the resonator without LICU application served as controls. All experiments
were performed in triplicate (i.e., from 3 different mice).
2.6. Immunofluorescence Staining of PANC-1 Tumor Explants
The ultrasound-treated and control PANC-1 tumor explants were fixed, permeabilized,
and serum-blocked as per standard procedures. They were then labelled with CD31 (1:100, Millipore,
Taunton, MA, USA) and Collagen I (1:500. AbCAM, Cambridge, MA, USA) overnight at 4 ◦C. Appropriate,
fluorescently labelled secondary antibodies were applied for 60 min and washed three times with saline.
Cell nuclei were stained with DAPI nuclear stain (Invitrogen, Waltham, MA, USA, 1:200) and washed
three more times with saline prior to confocal microscopy.
2.7. ELISAs for Inflammation
The V-PLEX Proinflammatory Panel 1 (human) ELISA Kit (Meso Scale Discovery, Rockville,
MD, USA) was used to assay cytokine release following ultrasound exposure. Culture media was
collected from control PANC-1 tumor explants (No US) and from explants exposed to 120 min of US.
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The Proinflammatory Panel 1 measures the following cytokines, which are important in inflammation
response and immune system regulation: IFN-γ, IL-10, IL-12, IL-1β, IL-2, IL-4, IL-5, IL-6, and TNF-α.
2.8. Image Acquisition
Bright field and fluorescence images were acquired with a Nikon SMZ1500 stereomicroscope
(Nikon Instruments Inc., Melville, NY, USA) equipped with a Nikon D90 SLR camera and a QIClickTM
digital CCD camera (QImaging, Surrey, BC, Canada). Confocal fluorescence images were acquired with
an Olympus IX81 microscope (20× air lens) equipped with the Fluoview software. Slice thickness
varied between 1 mm and 5 mm. Projections of confocal images were produced using Image J
(NIH, Bethesda, MA, USA).
2.9. Statistical Analysis
The data are shown as mean ± SEM. Data are normalised relative to control, non-ultrasound
treated samples. Analysis of means was performed with a one-way analysis of variance (ANOVA)
(GraphPad Prism software, La Jolla, CA, USA). Differences were considered significant at p values less
than 0.05. ****: p < 0.00005; ***: p < 0.0005; **: p < 0.005; *: p < 0.05.
3. Results and Discussion
Our experiments were performed at intensity levels significantly lower than a tissue injury
threshold: average intensities up to 30 kW/cm2 for a total duration of 10 min are safe in organs such as
kidneys [27], and a spatial peak intensity threshold of 16,620 W/cm2 was needed before a statistically
significant portion of the samples showed injury. This is nearly seven times the 2400 W/cm2 maximum
output of a clinical prototype used to move kidney stones effectively in pigs and more than 30 times
the intensity generated in our acoustic resonator.
3.1. Mechanical and Thermal Effects on the Samples
In our experiments, tumor explants displayed no apparent motion or deformation under LICU
but remained dynamically stable. This is a typical effect caused by high intensity focused ultrasound
(HIFU), which can lead to the destruction of the normal tissue.
In our experiments, a temperature rise of 1.0 ◦C was detected following two hours of acoustic
application (Table 1) at room temperature (20 ◦C). Such temperature rise represents an increase of 5%
over its initial value and is approximately six times smaller than that found by Draper et al. [31,32] in
muscle tissues exposed to focused waves. They reported a temperature increase of 5.8 ◦C at 0.8 and
1.6 cm tissue depths after 20 min of ultrasound application (f = 3 MHz and I = 1 W/cm2), and a 6 ◦C
rise following 120 s of exposure to focused LIPUS on brain tissue. The thermal effects on the tumor
explants exposed to LICU can thus be considered negligible.
Table 1. Temperature measurements inside the treatment chamber at different ultrasound
application times.
Time of Ultrasound Application (min) Temperature (◦C)
0 20.1
5 20.2
10 20.2
30 20.3
60 20.6
120 21.1
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3.2. LICU Effects on Cytokine Secretion, Tumor Vasculature, and Collagen I Production
The results of the cytokine array (Figure 2) showed that after LICU stimulation, IFN-γ,
was significantly upregulated by 3-fold compared to control, non-LICU-treated samples. In addition,
IL1-β was significantly upregulated by 16-fold, while TNF-α was upregulated 17-fold compared to
control, non LICU-treated samples (Figure 2). In contrast, IL-10, IL-12, IL-2, IL-4, IL-5, and IL-6 did not
significantly increase following LICU treatment. Cytokines are particularly important in the neoplastic
initiation; they are aberrantly produced by tumor cells, macrophages, and other phagocytic cells.
In pancreatic cancer, various signaling pathways are perturbed, and this not only affects the tumor cells
directly but also influences the stromal cells within and around the tumor [32]. In particular, NF-κB
signaling is commonly deregulated in PDAC [33]. A major activator of NF-κB is the cytokine tumor
necrosis factor (TNF), which is mainly produced by activated immune cells, especially macrophages
and T cells, but can also be expressed by tumor cells [34]. However, the role of TNF in pancreatic tumor
progression still remains controversial. While some studies demonstrated anti-tumorigenic properties
of TNF [35,36], others have shown the opposite results [37,38]. The 17-fold increase, in TNF-α following
LICU thus remains to be further explored.
Figure 2. Enzyme linked immunosorbent assay (ELISA) results of the V-PLEX Proinflammatory panel 1.
IFN-γ was significantly upregulated 3-fold; IL-β was significantly upregulated by 16-fold, while TNF-α
was upregulated 17-fold compared to control, non-low intensity continuous ultrasound (LICU)-treated
samples. IL-10, IL-12, IL-2, IL-4, IL-5, and IL-6 did not significantly increase following LICU treatment.
**: p < 0.005; *: p < 0.05.
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One of the key features of pancreatic cancer is extended fibrosis, which has been linked to the
activation of pancreatic stellate cells (PSCs) [39]. The desmoplastic reaction not only accompanies the
disease but plays an active role in its progression and reduces the efficiency of cytostatic drugs [40,41].
Interferon-γ (IFNγ) has been shown to inhibit fibrogenesis by targeting PSCs [42], and thus it has been
proposed as an active component for the treatment of pancreatic cancer as part of a chemoradiation
protocol [43,44]. Here, we report on a 3-fold increase in IFNγ, suggesting that LICU localized
application could be employed as a method to enhance the anti-fibrotic and anti-proliferative effect
of IFNγ.
We also demonstrate a significant increase in IL-1β secretion. High plasma IL-1β levels are
associated with a significantly increased risk of cancer, and tumor patients with high IL-1 expression
have worse prognosis [45]. IL-1 is a key modulator for induction of innate immunity and inflammation
and is a major pathogenic mediator of autoimmune, inflammatory, and infectious diseases [46].
IL-1β promotes invasiveness, including tumor angiogenesis, and also induces immune suppression
in the host [38,47]. In pancreatic cancer cells, IL-1β mediates adhesion and invasion, and modulates
chemoresistance by activating the NF-κB and ERK signaling pathways [41,48].
Finally, in order to investigate the effects of LICU on the vasculature, as well as the collagen
production of PANC-1 tumor explants, we exposed the tumor explants to 2 h of LICU. Tumor explants
were subsequently fixed and stained for CD31 and Collagen I. Our results (Figure 3) indicate that
while IL-10, IL-12, IL-2, IL-4, IL-5, and IL-6 did not significantly increase following LICU treatment,
the differential LICU effects on the secretion of cytokines suggest that further in vitro and in vivo
animal studies are required to elucidate LICU’s effects on tumor progression, while one cannot exclude
co-administration with chemotherapeutic agents to enhance LICU’s potential anti-tumorigenic effects.
Figure 3. Confocal immunofluorescence images of mouse pancreatic tumor explants. Application of
LICU for 2 h had no detectable effect on tumor vasculature (green) and collagen I (red) deposition.
Cell nuclei were stained with DAPI (blue). Scale bar is 250 µm.
A novel observation in our study was that the tumor explants exhibited a homogeneous spatial
behavior after the action of the ultrasonic standing waves was established within the chamber,
with amplitudes that were spatially variable (Figure 1B). This finding describes for the first time
the ability of cells and the extracellular matrix to provide a single-unit response to spatially variable
acoustic waves above their different acoustic stimuli at different sample locations. The samples
displayed in Figure 3 have a size of ~300 µm, covering an area of pressure amplitude pattern ~λ/4.
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However, no differences were observed in the temporal evolution between different parts of each of
these samples (in their vessels, DAPI, or collagen expression).
4. Conclusions
This work describes, for the first time, the effects that result from LICU being induced in tumor
tissues. We demonstrate that application of LICU on mouse pancreatic tumor explants results in
significant upregulation of the inflammatory cytokines IFN-γ, IL-β, and TNF-α. We also demonstrate
the feasibility of the application of LICU for long times, which is approximately six times those applied
by conventional LIPUS actuation without cell death in the limit condition of an infinite wave-train
length for a LIPUS, i.e., LICU actuation.
Our observations describe, for the first time, the ability of cells and the extracellular matrix to
provide a unitary response to acoustic waves with spatial variations in order of sample size. Ultrasonic
waves that are strongly variable in space generate effects that are variable also in granulated material
or suspensions of particles or cells associated with the gradient of radiation forces or other mechanisms
that are acoustically induced. On the contrary, the continuity of the organic tissue and the continuous
performance of LICU has probably generated a uniform response in our samples. It is a valuable
finding from a strategic point of view, since it reduces the spatial restrictions of the acoustic wave,
which often represents a technological problem.
In addition, we demonstrate the ability of the low intensity continuous ultrasound technology
to stimulate a pro-inflammatory response in tissues and tumors. LICU can be further explored as
a method to modulate the inflammatory response of tumors, with further potential for anti-tumorigenic
effects, and can thus be considered as strategic tool for therapeutic purposes.
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